|View printer-friendly version|
BeyondSpring’s Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium on Medical Oncology and 7th Annual Meeting of the Chinese Association for Clinical Oncologists
“In clinical studies to date, Plinabulin has demonstrated dual functions: First, in maintaining neutrophil counts within the normal range to prevent CIN, as well as anti-cancer efficacy in terms of prolonging the duration of anti-cancer response (DoR) in NSCLC patients, compared to docetaxel alone, with the aim of increasing overall survival,” said Dr. Shi, Director of the
Dr. Shi presented the results of Phase 2 of Study 105, demonstrating that patients treated with Plinabulin reported less bone pain while being equally protected against severe neutropenia compared to patients treated with Neulasta® (pegfilgrastim), a long-acting G-CSF. G-CSF accelerates maturation and proliferation of neutrophil precursors in bone marrow, and is given 24 hours after chemotherapy and causes severe bone pain in some patients. The Phase 2 data showed that patients who were given Plinabulin maintained median absolute neutrophil counts within normal range, whereas Neulasta caused median absolute neutrophil counts much higher than the normal range, which may lead to bone marrow exhaustion and suppression of the immune system.
“There is a growing body of scientific evidence suggesting that Plinabulin has the potential for a superior overall product profile in preventing CIN compared to Neulasta, and as evidenced by positive physician feedback on our scientific presentations and educational initiatives to date. There is increasing awareness within the medical community— particularly among Chinese oncologists who regularly treat patients with chemotherapy—of Plinabulin’s significant potential, which could help build momentum in our launch efforts in
About Chemotherapy-Induced Neutropenia (CIN)
The current standard of care for prevention of CIN is G-CSF, which accelerates maturation and proliferation of neutrophil precursors, and, when administered the day after chemotherapy, reduces DSN of docetaxel to less than one day. G-CSF stimulates the expansion and proliferation of neutrophil precursors in the central part (medullary compartment) of bone marrow, which may cause severe bone pain, leading to discontinuation of chemotherapy treatment. G-CSF also has the limitation of second-day dosing after chemotherapy treatment. For the intermediate-risk chemotherapy market, which represents 60 percent of cases, NCCN guidelines recommend G-CSF treatment only in limited, patient-specific circumstances.
Global sales of G-CSF totaled more than
Cautionary Note Regarding Forward-Looking Statements
Neulasta is a registered trademark of